Longxing Cao

Longxing Cao

Auto-generated profile, based on publicly available information

Longxing Cao

School of Life Sciences, Westlake University, Hangzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in Science
Verified
Journal Article
Open access
PDF file
LCLongxing Cao
Longxing Cao
IGInna Goreshnik
Inna Goreshnik
BCBrian Coventry
Brian Coventry
JCJames Brett Case
James Brett Case
LMLauren Miller
Lauren Miller
DBDavid Baker
David Baker
Miniproteins against SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is decorated with spikes, and viral entry into cells is initiated when these spikes bind to the host angiotensin-converting enzyme 2 (ACE2) receptor. Many monoclonal antibody therapies in development target the spike proteins. Cao et al. designed small, stable proteins that bind tightly to the spike and block it from binding to ACE2. The best designs bind with very high affinity and prevent SARS-CoV-2 infection of mammalian Vero E6 cells. Cryo–electron microscopy shows that the structures of the two most potent inhibitors are nearly identical to the computational models. Unlike antibodies, the miniproteins do not require expression in mammalian cells, and their small size and high stability may allow formulation for direct delivery to the nasal or respiratory system. Science , this issue p. 426

25 May 2022 in Science Translational Medicine
Verified
Journal Article
Open access
AHAndrew C. Hunt
Andrew C. Hunt
JCJames Brett Case
James Brett Case
YPYoung-Jun Park
Young-Jun Park
LCLongxing Cao
Longxing Cao
KWKejia Wu
Kejia Wu
DBDavid Baker
David Baker
New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2. We found the broadest efficacy was achieved with a homotrimeric version of the 75-residue angiotensin-converting enzyme 2 (ACE2) mimic AHB2 (TRI2-2) designed to geometrically match the trimeric spike architecture. Consistent with the design model, in the cryo-electron microscopy structure TRI2-2 forms a tripod at the apex of the spike protein that engaged all three receptor binding domains simultaneously. TRI2-2 neutralized Omicron (B.1.1.529), Delta (B.1.617.2), and all other variants tested with greater potency than the monoclonal antibodies used clinically for the treatment of COVID-19. TRI2-2 also conferred prophylactic and therapeutic protection against SARS-CoV-2 challenge when administered intranasally in mice. Designed miniprotein receptor mimics geometrically arrayed to match pathogen receptor binding sites could be a widely applicable antiviral therapeutic strategy with advantages over antibodies in greater resistance to viral escape and antigenic drift, and advantages over native receptor traps in lower chances of autoimmune responses.

17 October 2024 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
ZXZhen Xia
Zhen Xia
QJQihan Jin
Qihan Jin
ZLZhilin Long
Zhilin Long
YHYexuan He
Yexuan He
FLFuyi Liu
Fuyi Liu
QXQi Xie
Qi Xie

28 August 2025 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
BYBowen Yu
Bowen Yu
JLJiao Liu
Jiao Liu
ZCZhanyuan Cui
Zhanyuan Cui
CWChu Wang
Chu Wang
PCPeipei Chen
Peipei Chen
LCLongxing Cao
Longxing Cao

12 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CWChentong Wang
Chentong Wang
YQYannan Qu
Yannan Qu
ZPZhangzhi Peng
Zhangzhi Peng
YWYukai Wang
Yukai Wang
HZHongli Zhu
Hongli Zhu
LCLongxing Cao
Longxing Cao
Diffusion-based generative models have been successfully employed to create proteins with novel structures and functions. However, the construction of such models typically depends on large, pre-trained structure prediction networks, like RFdiffusion. In contrast, alternative models that are trained from scratch, such as FrameDiff, still fall short in performance. In this context, we introduce Proteus, an innovative deep diffusion network that incorporates graph-based triangle methods and a multi-track interaction network, eliminating the dependency on structure prediction pre-training with superior efficiency. We have validated our model’s performance on de novo protein backbone generation through comprehensive in silico evaluations and experimental characterizations, which demonstrate a remarkable success rate. These promising results underscore Proteus’s ability to generate highly designable protein backbones efficiently. This capability, achieved without reliance on pre-training techniques, has the potential to significantly advance the field of protein design. Codes are available at https://github.com/Wangchentong/Proteus .

1 January 2026 in Science
Verified
Journal Article
Closed access
QJQihan Jin
Qihan Jin
YWYukai Wang
Yukai Wang
DCDachuan Chen
Dachuan Chen
JLJinyang Liao
Jinyang Liao
ZCZhanyuan Cui
Zhanyuan Cui
LCLongxing Cao
Longxing Cao
Small molecule–regulated protein oligomerization provides a powerful mechanism for manipulating biological processes by controlling protein proximity with high temporal precision. However, such systems only rarely exist in nature and remain a substantial challenge for de novo design. In this work, we describe a computational method for designing protein homooligomers whose assembly is regulated by small-molecule ligands with matching symmetry. We designed protein homotrimers regulated by the Food and Drug Administration (FDA)–approved drug amantadine and further designed amantadine-responsive heterodimers and heterotrimers. Biophysical characterization confirmed their amantadine-dependent assembly, and their crystal structures closely matched the design models. We demonstrated their broad applicability in controlling protein localization, membraneless condensate formation, and gene expression. Our approach opens new avenues for designing small molecule–responsive proteins and expands the chemogenetic toolkit for manipulating complex biological processes.